目的 分析 2 型糖尿病(T2DM)合并慢性心力衰竭(CHF)患者经达格列净治疗后的临床疗效及其血糖控制效果.方法 120 例 2 型糖尿病合并慢性心力衰竭患者,经随机数字表法分为对照组与观察组,每组 60 例.对照组经常规治疗后给予二甲双胍缓释片治疗,观察组经常规治疗后给予达格列净治疗.对比两组患者的临床疗效及治疗前后血糖指标[空腹血糖(FPG)、餐后 2 h血糖(2 h PBG)、糖化血红蛋白(HbA1c)]、心功能指标[心率(HR)、B型脑利钠前体(pro-BNP)、左心室射血分数(LVEF)]水平.结果 相较于对照组(83.33%),观察组治疗总有效率(95.00%)较高,差异有统计学意义(P<0.05).治疗前,两组FPG、2 h PBG、HbA1c对比差异不具有统计学意义(P>0.05);治疗后,观察组FPG(8.02±0.12)mmol/L、2 h PBG(8.12±0.11)mmol/L、HbA1c(6.21±0.12)%低于对照组的(8.71±0.25)mmol/L、(9.25±0.21)mmol/L、(7.21±0.14)%,差异有统计学意义(P<0.05).治疗前,两组HR、pro-BNP、LVEF对比差异不具有统计学意义(P>0.05);治疗后,观察组HR(75.28±3.48)次/min、pro-BNP(58.24±5.87)ng/L低于对照组的(85.36±3.54)次/min、(123.36±5.24)ng/L,LVEF(58.63±3.58)%高于对照组的(52.36±3.47)%,差异有统计学意义(P<0.05).结论 经达格列净治疗后,2 型糖尿病合并慢性心力衰竭患者血糖控制效果极佳,且心功能已逐渐恢复正常,治疗效果十分显著.
Study on clinical efficacy of dapagliflozin in T2DM patients with CHF and its effect on blood glucose control
Objective To analyze the clinical efficacy of dapagliflozin in type 2 diabetes mellitus(T2DM)patients with chronic heart failure(CHF)and its effect on blood glucose control.Methods 120 cases cases of T2DM patients with CHF were divided into a control group and an observation group by a random number table method,with 60 cases in each group.Both groups received routine treatment,on this basis,the control group was treated with metformin sustained-release tablets,and the observation group was treated with dapagliflozin.Patients in both groups were compared in terms of clinical efficacy,blood glucose indicators[fasting plasma glucose(FPG),2-h postprandial blood glucose(2-h PBG),glycated hemoglobin(HbA1c)]and cardiac function indicators[heart rate(HR),pro-brain natriuretic peptide(pro-BNP),left ventricular ejection fraction(LVEF)]before and after treatment.Results Compared with the control group(83.33%),the total effective rate of the observation group(95.00%)was higher,and the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in FPG,2 h PBG and HbA1c between the two groups(P>0.05).After treatment,the observation group had FPG of(8.02±0.12)mmol/L,2 h PBG of(8.12±0.11)mmol/L and HbA1c of(6.21±0.12)%,which were lower than(8.71±0.25)mmol/L,(9.25±0.21)mmol/L and(7.21±0.14)%in the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in HR,pro-BNP and LVEF between the two groups(P>0.05).After treatment,the observation group had HR of(75.28±3.48)beats/min and pro-BNP of(58.24±5.87)ng/L,which were lower than(85.36±3.54)beats/min and(123.36±5.24)ng/L in the control group;the observation group had higher LVEF of(58.63±3.58)%than(52.36±3.47)%in the control group;the difference was statistically significant(P<0.05).Conclusion After dapagliflozin treatment,patients with T2DM combined with CHF have excellent blood glucose control,and their heart function has gradually returned to normal,and the treatment effect is very significant.
Type 2 diabetes mellitusChronic heart failureDapagliflozinBlood glucoseCardiac function
万方数据
维普
